Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지
DOI QR코드

DOI QR Code

The effects of pentoxifylline and tocopherol in jaw osteomyelitis

  • Seo, Mi Hyun (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Eo, Mi Young (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Myoung, Hoon (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Kim, Soung Min (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University) ;
  • Lee, Jong Ho (Department of Oral and Maxillofacial Surgery, School of Dentistry and Dental Research Institute, Seoul National University)
  • Received : 2018.09.29
  • Accepted : 2018.10.09
  • Published : 2020.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Pentoxifylline (PTX) is a methylxanthine derivative that has been implicated in the pathogenesis of peripheral vessel disease and intermittent lameness. The purpose of this study was to investigate the effect of PTX and tocopherol in patients diagnosed with osteoradionecrosis (ORN), bisphosphonate-related osteonecrosis of the jaw (BRONJ), and chronic osteomyelitis using digital panoramic radiographs. Materials and Methods: This study was performed in 25 patients who were prescribed PTX and tocopherol for treatment of ORN, BRONJ, and chronic osteomyelitis between January 2014 and May 2018 in Seoul National University Dental Hospital. Radiographic densities of the dental panorama were compared prior to starting PTX and tocopherol, at 3 months, and at 6 months after prescription. Radiographic densities were measured using Adobe Photoshop CS6 (Adobe System Inc., USA). Blood sample tests showing the degree of inflammation at the initial visit were considered the baseline and compared with results after 3 to 6 months. Statistical analysis was performed using the Mann-Whitney test and repeated measurement ANOVA using IBM SPSS 23.0 (IBM Corp., USA). Results: Eight patients were diagnosed with ORN, nine patients with BRONJ, and the other 8 patients with chronic osteomyelitis. Ten of the 25 patients were men, average age was 66.32±14.39 years, and average duration of medication was 151.8±80.65 days (range, 56-315 days). Statistically significant increases were observed in the changes between 3 and 6 months after prescription (P<0.05). There was no significant difference between ORN, BRONJ, and chronic osteomyelitis. Only erythrocyte sedimentation rate (ESR) was statistically significantly lower than before treatment (P<0.05) among the white blood cell (WBC), ESR, and absolute neutrophil count (ANC). Conclusion: Long-term use of PTX and tocopherol can be an auxiliary method in the treatment of ORN, BRONJ, or chronic osteomyelitis in jaw.

Keywords

References

  1. Martos-Fernandez M, Saez-Barba M, Lopez-Lopez J, Estrugo-Devesa A, Balibrea-Del-Castillo JM, Bescos-Atin C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125:431-9. https://doi.org/10.1016/j.oooo.2018.02.004
  2. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97. https://doi.org/10.2165/00003495-198734010-00003
  3. Magnusson M, Gunnarsson M, Berntorp E, Bjorkman S, Hoglund P. Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. Eur J Pharmacol 2008;581:290-5. https://doi.org/10.1016/j.ejphar.2007.11.054
  4. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994;83:262-7.
  5. Lyons AJ, Brennan PA. Pentoxifylline: a review of its use in osteo radionecrosis. Br J Oral Maxillofac Surg 2017;55:230-4. https://doi.org/10.1016/j.bjoms.2016.12.006
  6. Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck 2005;27:114-23. https://doi.org/10.1002/hed.20121
  7. Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys 2011;80:832-9. https://doi.org/10.1016/j.ijrobp.2010.03.029
  8. Qaisi M, Montague L. Bone margin analysis for osteonecrosis and osteomyelitis of the jaws. Oral Maxillofac Surg Clin North Am 2017;29:301-13. https://doi.org/10.1016/j.coms.2017.03.007
  9. Notani K, Yamazaki Y, Kitada H, Sakakibara N, Fukuda H, Omori K, et al. Management of mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the method of radiotherapy. Head Neck 2003;25:181-6. https://doi.org/10.1002/hed.10171
  10. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
  11. Ruggiero SL. Diagnosis and staging of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am 2015;27:479-87. https://doi.org/10.1016/j.coms.2015.06.008
  12. Futran ND, Trotti A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Laryngoscope 1997;107:391-5. https://doi.org/10.1097/00005537-199703000-00022
  13. Zhao Y, Liu B, Wang SP, Wang YN. Computed densitometry of panoramic radiographs in evaluation of bone healing after enucleation of mandibular odontogenic keratocysts. Chin J Dent Res 2010;13:123-6.
  14. White SC, Mallya SM. Update on the biological effects of ionizing radiation, relative dose factors and radiation hygiene. Aust Dent J 2012;57 Suppl 1:2-8. https://doi.org/10.1111/j.1834-7819.2011.01665.x
  15. Mallya SM, Tetradis S. Imaging of radiation- and medicationrelated osteonecrosis. Radiol Clin North Am 2018;56:77-89. https://doi.org/10.1016/j.rcl.2017.08.006
  16. Delanian S, Lefaix JL. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 2004;73:119-31. https://doi.org/10.1016/j.radonc.2004.08.021
  17. McLeod NM, Pratt CA, Mellor TK, Brennan PA. Pentoxifylline and tocopherol in the management of patients with osteoradionecrosis, the Portsmouth experience. Br J Oral Maxillofac Surg 2012;50:41-4. https://doi.org/10.1016/j.bjoms.2010.11.017
  18. D'Souza J, Lowe D, Rogers SN. Changing trends and the role of medical management on the outcome of patients treated for osteoradionecrosis of the mandible: experience from a regional head and neck unit. Br J Oral Maxillofac Surg 2014;52:356-62. https://doi.org/10.1016/j.bjoms.2014.01.003
  19. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:593-6. https://doi.org/10.1016/j.tripleo.2010.05.067
  20. Magremanne M, Reychler H. Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. J Oral Maxillofac Surg 2014;72:334-7. https://doi.org/10.1016/j.joms.2013.06.188
  21. Owosho AA, Estilo CL, Huryn JM, Yom SK. Pentoxifylline and tocopherol in the management of cancer patients with medicationrelated osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122:455-9. https://doi.org/10.1016/j.oooo.2016.06.019
  22. Boerma M, Roberto KA, Hauer-Jensen M. Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol. Int J Radiat Oncol Biol Phys 2008;72:170-7. https://doi.org/10.1016/j.ijrobp.2008.04.042
  23. Rube CE, Wilfert F, Uthe D, Schmid KW, Knoop R, Willich N, et al. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 2002;64:177-87. https://doi.org/10.1016/S0167-8140(02)00077-4
  24. Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 2005;23:8570-9. https://doi.org/10.1200/JCO.2005.02.4729

Cited by

  1. Maxillo-mandibular osteoradionecrosis following C-ion radiotherapy: Clinical notes and review of literature vol.18, 2020, https://doi.org/10.1177/2058739220934562
  2. Essential review points on the retrospective study of osteoradionecrosis in the jaws vol.46, pp.3, 2020, https://doi.org/10.5125/jkaoms.2020.46.3.208
  3. Reply to the brief communication "Essential review points on the retrospective study of osteoradionecrosis in the jaws" vol.46, pp.6, 2020, https://doi.org/10.5125/jkaoms.2020.46.6.440
  4. Author's reply to the letter to the editor of Journal of the Korean Association of Oral and Maxillofacial Surgeons vol.46, pp.6, 2020, https://doi.org/10.5125/jkaoms.2020.46.6.442
  5. The Potential Therapeutic Role of Mesenchymal Stem Cells-Derived Exosomes in Osteoradionecrosis vol.2021, 2020, https://doi.org/10.1155/2021/4758364